MX2018014876A - Dominios tipo iii de fibronectina de unión a albúmina sérica. - Google Patents
Dominios tipo iii de fibronectina de unión a albúmina sérica.Info
- Publication number
- MX2018014876A MX2018014876A MX2018014876A MX2018014876A MX2018014876A MX 2018014876 A MX2018014876 A MX 2018014876A MX 2018014876 A MX2018014876 A MX 2018014876A MX 2018014876 A MX2018014876 A MX 2018014876A MX 2018014876 A MX2018014876 A MX 2018014876A
- Authority
- MX
- Mexico
- Prior art keywords
- domains
- serum albumin
- type iii
- fibronectin type
- iii domains
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
- G01N2333/765—Serum albumin, e.g. HSA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
Abstract
Dominios tipo III de fibronectina (FN3) que se unen especificamente a albumina serica, polinucleotidos relacionados capaces de codificar dominios FN3 especificos de albumina serica, celulas que expresan los dominios FN3, asi como tambien vectores asociados, dominios FN3 etiquetados de manera detectable, y dominios FN3 fusionados a una porcion heterologa son utiles para extender la vida media de moleculas en aplicaciones de diagnostico y terapeuticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662345190P | 2016-06-03 | 2016-06-03 | |
PCT/US2017/035442 WO2017210425A1 (en) | 2016-06-03 | 2017-06-01 | Serum albumin-binding fibronectin type iii domains |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018014876A true MX2018014876A (es) | 2019-05-22 |
Family
ID=60477987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018014876A MX2018014876A (es) | 2016-06-03 | 2017-06-01 | Dominios tipo iii de fibronectina de unión a albúmina sérica. |
Country Status (13)
Country | Link |
---|---|
US (3) | US10925932B2 (es) |
EP (1) | EP3463430A4 (es) |
JP (2) | JP7111627B2 (es) |
KR (1) | KR102461666B1 (es) |
CN (1) | CN109562146A (es) |
AU (1) | AU2017273743B2 (es) |
EA (1) | EA201892796A1 (es) |
IL (2) | IL263347B (es) |
MA (1) | MA45186A (es) |
MX (1) | MX2018014876A (es) |
SG (1) | SG11201810687SA (es) |
UA (1) | UA126021C2 (es) |
WO (1) | WO2017210425A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014334627B2 (en) | 2013-10-14 | 2019-07-25 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type III domain binding molecules |
MA45186A (fr) * | 2016-06-03 | 2019-04-10 | Janssen Biotech Inc | Domaines de fibronectine de type iii se liant à l'albumine sérique |
US10662235B2 (en) * | 2016-06-21 | 2020-05-26 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type III domain binding molecules |
US10597438B2 (en) | 2016-12-14 | 2020-03-24 | Janssen Biotech, Inc. | PD-L1 binding fibronectin type III domains |
WO2018111978A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
WO2018111973A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd8a-binding fibronectin type iii domains |
CN110724198B (zh) * | 2018-07-17 | 2023-05-26 | 上海一宸医药科技有限公司 | 长效纤连蛋白iii型结构域融合蛋白 |
WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
CN114786682A (zh) * | 2019-10-14 | 2022-07-22 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
USD1021702S1 (en) * | 2021-10-20 | 2024-04-09 | GM Global Technology Operations LLC | Vehicle center grille |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE30985E (en) * | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) * | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
EP0435911B1 (en) * | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
AU638762B2 (en) * | 1989-10-05 | 1993-07-08 | Optein Inc | Cell-free synthesis and isolation of novel genes and polypeptides |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US5122469A (en) * | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
ATE463573T1 (de) * | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
PT752248E (pt) | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
AU5670194A (en) * | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
JP3614866B2 (ja) * | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ,インコーポレイティド | 人工抗体ポリペプチド |
ATE352559T1 (de) * | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
US6472147B1 (en) * | 1999-05-25 | 2002-10-29 | The Scripps Research Institute | Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries |
US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
CA2390691C (en) * | 1999-12-24 | 2016-05-10 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
US20130226834A1 (en) | 2000-04-27 | 2013-08-29 | Networth Services, Inc. | Systems and methods for determining the financial status of bonds |
JP4602614B2 (ja) * | 2001-09-26 | 2010-12-22 | アイシン精機株式会社 | 自動車用ドア |
JP2006512895A (ja) * | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | リガンド |
DE60335000D1 (de) * | 2002-09-06 | 2010-12-30 | Isogenica Ltd | In vitro peptid-expressionsbank |
CA2710378A1 (en) * | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Engineered phage vectors for the design and the generation of a human non-antibody peptide or protein phage library via fusion to pix of m13 phage |
ES2564523T3 (es) | 2007-12-19 | 2016-03-23 | Janssen Biotech, Inc. | Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos |
AU2009308935B2 (en) * | 2008-10-31 | 2015-02-26 | Janssen Biotech, Inc. | Fibronectin type III domain based scaffold compositions, methods and uses |
EP2396011B1 (en) * | 2009-02-12 | 2016-04-13 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
EP3569256B1 (en) * | 2010-04-30 | 2022-06-15 | Janssen Biotech, Inc. | Stabilized fibronectin domain compositions, methods and uses |
TW201138808A (en) * | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
CN103180339B (zh) * | 2010-05-26 | 2016-04-27 | 百时美施贵宝公司 | 具有改善的稳定性的基于纤连蛋白的支架蛋白质 |
BR112014007469B1 (pt) * | 2011-09-27 | 2022-06-14 | Janssen Biotech, Inc | Método de fabricação de uma biblioteca de domínios de módulo de fibronectina tipo iii (fn3), biblioteca e método para obter um arcabouço de proteína |
US9695228B2 (en) * | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
KR20160097294A (ko) * | 2013-12-09 | 2016-08-17 | 뉴욕 유니버시티 | 항-포도상구균 제제의 식세포 전달을 위한 조성물 및 방법 |
KR20220162886A (ko) | 2014-03-20 | 2022-12-08 | 브리스톨-마이어스 스큅 컴퍼니 | 혈청 알부민-결합 피브로넥틴 유형 iii 도메인 |
JP2018517708A (ja) * | 2015-06-05 | 2018-07-05 | ニューヨーク・ユニバーシティ | 抗ブドウ球菌生物学的薬剤のための組成物及び方法 |
MA45186A (fr) * | 2016-06-03 | 2019-04-10 | Janssen Biotech Inc | Domaines de fibronectine de type iii se liant à l'albumine sérique |
US10662235B2 (en) * | 2016-06-21 | 2020-05-26 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type III domain binding molecules |
-
2017
- 2017-06-01 MA MA045186A patent/MA45186A/fr unknown
- 2017-06-01 CN CN201780047969.6A patent/CN109562146A/zh active Pending
- 2017-06-01 SG SG11201810687SA patent/SG11201810687SA/en unknown
- 2017-06-01 EP EP17807478.7A patent/EP3463430A4/en active Pending
- 2017-06-01 EA EA201892796A patent/EA201892796A1/ru unknown
- 2017-06-01 MX MX2018014876A patent/MX2018014876A/es unknown
- 2017-06-01 JP JP2018562935A patent/JP7111627B2/ja active Active
- 2017-06-01 UA UAA201812826A patent/UA126021C2/uk unknown
- 2017-06-01 KR KR1020187037937A patent/KR102461666B1/ko active IP Right Grant
- 2017-06-01 AU AU2017273743A patent/AU2017273743B2/en active Active
- 2017-06-01 US US15/611,296 patent/US10925932B2/en active Active
- 2017-06-01 WO PCT/US2017/035442 patent/WO2017210425A1/en unknown
-
2018
- 2018-11-28 IL IL263347A patent/IL263347B/en active IP Right Grant
-
2021
- 2021-01-20 US US17/153,229 patent/US11833190B2/en active Active
- 2021-05-05 IL IL282960A patent/IL282960B/en unknown
- 2021-12-08 JP JP2021199610A patent/JP2022046510A/ja not_active Withdrawn
-
2023
- 2023-10-27 US US18/496,397 patent/US20240100129A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR102461666B1 (ko) | 2022-11-01 |
US20240100129A1 (en) | 2024-03-28 |
IL263347B (en) | 2021-05-31 |
CN109562146A (zh) | 2019-04-02 |
US20170348397A1 (en) | 2017-12-07 |
US20210228688A1 (en) | 2021-07-29 |
JP2019521662A (ja) | 2019-08-08 |
IL282960B (en) | 2022-03-01 |
EA201892796A1 (ru) | 2019-06-28 |
SG11201810687SA (en) | 2018-12-28 |
EP3463430A4 (en) | 2020-02-12 |
US10925932B2 (en) | 2021-02-23 |
IL282960A (en) | 2021-06-30 |
JP2022046510A (ja) | 2022-03-23 |
US11833190B2 (en) | 2023-12-05 |
WO2017210425A1 (en) | 2017-12-07 |
AU2017273743A1 (en) | 2019-01-03 |
AU2017273743B2 (en) | 2021-12-02 |
IL263347A (en) | 2018-12-31 |
KR20190013970A (ko) | 2019-02-11 |
MA45186A (fr) | 2019-04-10 |
EP3463430A1 (en) | 2019-04-10 |
UA126021C2 (uk) | 2022-08-03 |
JP7111627B2 (ja) | 2022-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018014876A (es) | Dominios tipo iii de fibronectina de unión a albúmina sérica. | |
MX2016011580A (es) | Dominios de fibronectina tipo iii que se unen a albumina de suero. | |
UY37340A (es) | Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas | |
BR112019012154A2 (pt) | domínios do tipo iii da fibronectina de ligação a cd8a | |
UY36974A (es) | Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas | |
MX2020011788A (es) | Acoplador trifuncional de antigeno de celulas t y metodos y usos del mismo. | |
WO2017053619A8 (en) | Glypican-3binding fibronectin based scafflold molecules | |
PH12018501280A1 (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use | |
MY181199A (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use | |
SG10201808811QA (en) | Method and compositions for cellular immunotherapy | |
TN2012000518A1 (en) | Serum albumin binding molecules | |
EP3912997A3 (en) | Binding molecules for bcma and cd3 | |
GB201008682D0 (en) | Epitope tag for affinity based applications | |
EA201500206A1 (ru) | Слитые белки, содержащие интерлейкин-2, и их применения | |
MX353382B (es) | Moleculas de union polipeptido de larga duracion. | |
MY186864A (en) | Fusion immunomodulatory proteins and methods for making same | |
NZ722055A (en) | Fcrn antagonists and methods of use | |
NZ760289A (en) | Interleukin-2 fusion proteins and uses thereof | |
SG10201909716RA (en) | Modified j-chain | |
MX2019008417A (es) | Cambio de temperatura para una expresion con mayor rendimiento de polipeptidos en levaduras y otras celulas transformadas. | |
MX2019000514A (es) | Anticuerpos de tgfb, métodos, y usos. | |
PH12018501902A1 (en) | Gitr antibodies, methods, and uses | |
NZ713904A (en) | Thrombin cleavable linker with xten and its uses thereof | |
MX2019007248A (es) | Enzimas de polimerizacion para reacciones de secuenciacion. | |
BR112016009755A2 (pt) | produção contínua de perfis em uma construção do tipo sanduíche com núcleos de espuma e perfil preenchido com espuma rígida. |